ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BVC.GB BATM Advanced Communications Limited

16.97
-0.85 (-4.77%)
29 Nov 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
BATM Advanced Communications Limited AQSE:BVC.GB Aquis Stock Exchange Ordinary Share IL0010849045
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.85 -4.77% 16.97 14.96 17.94 18.00 16.45 17.82 6,000 16:29:54
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

BATM Advanced Communications Ld ADOR Diagnostics secures $7.5m investment (8845Q)

23/10/2023 7:04am

UK Regulatory


BATM Advanced Communicat... (AQSE:BVC.GB)
Historical Stock Chart


From Nov 2022 to Nov 2024

Click Here for more BATM Advanced Communicat... Charts.

TIDMBVC

RNS Number : 8845Q

BATM Advanced Communications Ld

23 October 2023

LEI: 213800FLQUB9J289RU66

23 October 2023

BATM Advanced Communications Limited

("BATM" or the "Group")

ADOR Diagnostics secures $7.5m investment

BATM Advanced Communications Limited (LSE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that ADOR Diagnostics Ltd ("ADOR"), an associate company of the Group, has secured an investment of $7.5m, of which the Group is contributing $3.5m. Half of the investment is being made on the signing of the investment agreement and the remainder will be paid on the completion of milestones over the next six months. Following this investment, the Group's shareholding in ADOR will increase to 43.6%.

ADOR, a disruptive molecular diagnostics company, is developing the advanced NATlab molecular biology platform that uses a novel isothermal rolling circle amplification method for syndromic multiplex diagnostics, with a focus on infectious disease. This sample-to-answer solution is designed to provide rapid and accurate results, enabling exact pathogen detection and timely treatment. R&D continues to progress and pre-clinical trials are underway with a hospital. With 11 patents issued in the US and 8 internationally with others pending, the Group expects the total addressable market for NATlab to grow to $15.8bn by 2025.

Moti Nagar, CEO of BATM, said: "We are very excited about the groundbreaking potential of ADOR, which has a technology that is set to truly disrupt the molecular diagnostics market - and is backed by a strong and growing international patent portfolio. This investment, supported by our vast experience of transforming IP into market-ready products, will advance the development of ADOR towards what we believe will be a significant value creation opportunity for BATM. We look forward to reporting on ADOR's progress."

Enquiries

 
BATM Advanced Communications 
Moti Nagar, Chief Executive Officer        +972 9866 2525 
Ran Noy, Chief Financial Officer 
 
Shore Capital 
Mark Percy, Anita Ghanekar, James Thomas 
 (Corporate Advisory)                      +44 20 7408 4050 
 
Gracechurch Group 
Harry Chathli, Claire Norbury              +44 20 4582 3500 
 

Forward-looking statements

This document contains forward-looking statements. Those statements reflect the current opinions, evaluations and estimations of the Group's management, and are based on the current data regarding the Group's business as is detailed in this document and in the Group's periodical, interim and immediate reports. The Group does not undertake any obligation or make any representation that actual results and events will be in line with those statements, and stresses that they may differ materially from those statements, due to changes in the Group's business, market, competition, demand for the Group's products or services, general economic factors or other factors that can influence the Group's business and results, due to the risk factors that are detailed in the Group's Annual Report, and due to information and factors that are currently unknown to the Group's management and that, if known, would affect the management's opinions, evaluations or estimations. The Group will report the actual results and events according to its legal, accounting and regulatory obligations, and does not undertake any other obligation to report them or their deviations from the forward-looking statements, or to update any of the forward-looking statements in this document or to report that it is not valid anymore.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEANEAADFDFFA

(END) Dow Jones Newswires

October 23, 2023 02:04 ET (06:04 GMT)

1 Year BATM Advanced Communicat... Chart

1 Year BATM Advanced Communicat... Chart

1 Month BATM Advanced Communicat... Chart

1 Month BATM Advanced Communicat... Chart